IKT · Inhibikase Therapeutics, Inc. · Metrics
$1.71
+0.07 (+3.95%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$229.54M
Shares
139.54M
Volume · Oct 20
352.25K
Avg daily vol (3M)
604.94K
IKT metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.71
Market cap
$229.54M
Price action
20 metricsPrice change (1W)
-10.8%
Price change (30D)
-25.2%
Price change (3M)
-26.2%
Price change (6M)
-9.1%
Price change (YTD)
-19.8%
Price change (1Y)
+4.8%
Trailing year
Price change (5Y)
—
52-week high
$2.52
52-week low
$1.41
Change from 52-week high
-34.7%
Change from 52-week low
+16.7%
Annualized volatility
62.8%
Annualized volatility (3M)
53.2%
Beta
1.5
RSI (14D)
27.1
Price vs SMA 50
-25.9%
Price vs SMA 200
-15.5%
Avg volume (3M)
616,000
Relative volume
2.2
Average dollar volume
$1.36M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
139.54M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.5
reciprocal yield 66.6%
FCF yield
-18.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
18,212,356.5×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
18,212,356.5×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$65.44M
Net income (TTM)
−$60.64M
Trailing 12 months
Diluted EPS (TTM)
$-0.44
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+93.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-39.5%
Return on assets
-37.1%
Debt / equity
0.0
Current ratio
15.8
EBITDA (TTM)
—
Free cash flow (TTM)
−$42.61M
Quick ratio
15.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$159.02M
Latest balance sheet
Cash & equivalents
$31.21M
Total assets
$163.59M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$42.61M
Capital expenditures (TTM)
$0
R&D (TTM)
$38.24M
SG&A (TTM)
$27.42M
Stock compensation (TTM)
$19.96M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
105
13F filer change QoQ
+1
Institutional ownership
84.5%
Conviction holders (share of 13F filers)
2.9%
Crowding (high-turnover and private-fund holders)
55.4%
Private-fund adviser ownership
47.1%
Active holders' share change QoQ
0.0%
Holder tenure
5.8
Price vs estimated holder cost
+0.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
9.5%
Short interest
3 metricsShort interest
13.9%
Latest settlement · 27.0 days to cover
Days to cover
27.0d
Short-squeeze score
68 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—